Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Imatinib Mesylate

Criteria

Inclusion criteria:

• Patients ≥18 years of age

• Histologically documented diagnosis of malignant MPNST

• Unresectable local MPNST or metastatic MPNST and therefore incurable with any conventional multimodality approach Life expectancy of at least 6 months.

Exclusion criteria:

• Patient has received any other investigational agents within 28 days of first day of study drug dosing.

• Chemotherapy and or radiotherapy in between the last 6 weeks before study entry, surgery in between the last 14 days before study entry.

• Female patients who are pregnant or breast feeding or women of child bearing potential who are not using a highly effective method of birth control.

• Known CNS metastases

Other protocol-defined inclusion/exclusion criteria may apply.